UNITI-2

November 18, 2016November 18, 2016

Stelara, Treatment for Moderate-to-Severe Crohn’s Disease, Approved for Use in EU

News

The European Commission (EC) has approved Stelara (ustekinumab) for the treatment of adults with moderate-to-severe Crohn’s disease who had no improvements with other therapies, the drug developer’s, Janssen, announced. Stelara is ... Read more

September 23, 2016

European Agency Recommends Approval of Stelara to Treat Crohn’s Disease

News

The Committee for Medicinal Products for Human Use (CHMP), the scientific board of European Medicines Agency (EMA), has issued a positive opinion on Janssen’s Stelara (ustekinumab) for the treatment of patients with moderate-to-severe active ... Read more

October 22, 2015October 22, 2015

Crohn’s Disease Therapy STELARA Showed Efficacy in Phase III Trial

News

Results on a pivotal Janssen Research & Development, LLC-commissioned Phase III clinical trial, called UNITI-2, on STELARA® (ustekinumab) for moderate to severe Crohn’s disease were recently reported and provided the first evidence ... Read more